We Offer Worldwide Shipping
Login Wishlist

Esculin

$43

Brand : BIOFRON
Catalogue Number : BF-E1011
Specification : 98%
CAS number : 531-75-9
Formula : C15H16O9
Molecular Weight : 340.28
PUBCHEM ID : 5281417
Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-E1011

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

340.28

Appearance

White crystalline powder

Botanical Source

Fraxinus chinensis,Bidens pilosa,Bombax ceiba,Actinidia chinensis,Cardamine leucantha

Structure Type

Phenylpropanoids

Category

Standards;Natural Pytochemical;API

SMILES

C1=CC(=O)OC2=CC(=C(C=C21)OC3C(C(C(C(O3)CO)O)O)O)O

Synonyms

Crataegin/7-Hydroxy-2-oxo-2H-chromen-6-yl β-D-glucopyranoside/Enallachrome/vitaminc2/Esculetin 6-β-D-glucoside/POLYDROM/Bicolorin/Esculetin 6-O-glucoside/Polychrom/7-Hydroxy-2-oxo-2H-chromen-6-yl-β-D-glucopyranoside/BICOLOIN/7-Hydroxycoumarin-6-yl β-D-Glucopyranoside Sesquihydrate/Esculin/7-Hydroxy-6-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-2H-chromen-2-one/Polychrome/6-(β-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one/Esculetin 6-b-D-glucoside/2H-1-Benzopyran-2-one, 6-(β-D-glucopyranosyloxy)-7-hydroxy-/7-Hydroxy-2-oxo-2H-chromen-6-yl β-D-glucopyranoside hydrate (1:1)/Aesculin/Esculetin-6-O-glucoside/2H-1-Benzopyran-2-one, 6-(β-D-glucopyranosyloxy)-7-hydroxy-, hydrate (1:1)/Escosyl

IUPAC Name

7-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one

Density

1.7±0.1 g/cm3

Solubility

Methanol; Ethanol

Flash Point

262.8±25.0 °C

Boiling Point

697.7±55.0 °C at 760 mmHg

Melting Point

203 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2938900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:531-75-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

31202807

Abstract

Aesculin, a natural product from the traditional and widely-used Chinese medicine named Cortex fraxini, has attracted attention as a novel therapeutic modulator of inflammation. However, little is known about its effect on ulcerative colitis (UC). This study aimed to investigate the protective effects and mechanisms of aesculin on colitis. The results showed that, few cytotoxicity of aesculin were shown in vivo and in the RAW264.7 macrophages, while aesculin significantly relieved the symptoms of DSS-induced colitis and restrained the expression of inflammatory factors including iNOS, IL-1β, TNF-α in both peritoneal macrophages and colonic tissues from DSS-induced mice and RAW264.7 macrophages. Of note, aesculin attenuated the activity of NF-κB signaling while promoted the nuclear localization of PPAR-γ in both rectal tissues from DSS-induced mice and LPS-stimulated macrophages. These findings demonstrated that the protection of aesculin against ulcerative colitis might be due to its regulation on the PPAR-γ and NF-κB pathway. Thus, aesculin could serve as a potential therapeutic agent for the treatment of ulcerative colitis.

Copyright © 2019 Elsevier B.V. All rights reserved.

KEYWORDS

Aesculin; Macrophage; NF-κB; PPAR-γ; Ulcerative colitis

Title

Aesculin protects against DSS-Induced colitis though activating PPARγ and inhibiting NF-кB pathway.

Author

Tian X1, Peng Z2, Luo S3, Zhang S1, Li B1, Zhou C4, Fan H5.

Publish date

2019 Aug 15

PMID

30861618

Abstract

The Keap1-Nrf2-ARE system serves as a premier defence mechanism to curb oxidative stress, which remains as one of the major causes of ageing and pathogenesis in various diseases. Nrf2 is the principal master regulator of the cellular defence system, and its activation remains the prospective therapeutic approach against chronic diseases. One of the recent strategies is to disrupt Keap1-Nrf2 protein-protein interaction (PPI) that alters the docking of Keap1 with Nrf2 by compounds occupying a position in the Keap1 blocking the interface with Nrf2. In this study, we made an attempt to identify the compounds with anticancer, antioxidant and anti-inflammatory properties to disrupt Keap1a/b-Nrf2 PPI through in silico molecular docking in zebrafish. The phylogenetic analysis of Keap1 proteins revealed the existence of orthologous Keap1-Nrf2-ARE system in lower vertebrates that includes zebrafish. The DGR domains of zebrafish Keap1a and Keap1b were modelled with Modeller 9.19 using Keap1 of Mus musculus (PDB ID:5CGJ) as template. Based on the docking calculations, top hit compounds were identified to disrupt both Keap1a and Keap1b interaction with Nrf2 which include quercetin 3,4′-diglucoside, flavin adenine dinucleotide disodium salt hydrate, salvianolic acid A, tunicamycin and esculin. The LC50 of esculin in 3 dpf zebrafish larvae is 5 mmol/L, and the qRT-PCR results showed that esculin significantly increased the transcription of Nrf2 target genes-Gstpi, Nqo1, Hmox1a and Prdx1 in 3 dpf zebrafish larvae. These potential hits could serve as safer Nrf2 activators due to their non-covalent disruption of Keap1-Nrf2 PPI and be developed into efficacious preventive/therapeutic agents for various diseases.

© 2019 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

KEYWORDS

Keap1-Nrf2-ARE pathway; esculin; non-covalent interaction; oxidative stress; protein-protein interaction; zebrafish

Title

Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.

Author

Raghunath A1, Nagarajan R2, Sundarraj K1, Palanisamy K1, Perumal E1.

Publish date

2019 Sep

PMID

30733181

Abstract

Glucocorticoids are widely prescribed for lots of pathological conditions, however, can produce ‘Cushingoid’ side effects including central obesity, glucose intolerance, insulin resistance and so forth. Our study is intended to investigate the improving effects of coumarins on diabetogenic action of dexamethasone in vivo and in vitro and elucidate potential mechanisms. ICR mice treated with dexamethasone for 21 days exhibited decreased body weight, increased blood glucose and impaired glucose tolerance, which were prevented by fraxetin (40 mg/kg/day), esculin (40 mg/kg/day) and osthole (20 mg/kg/day), respectively. Esculin, fraxetin and osthole also could promote glucose uptake in normal C2C12 myotubes, and improve insulin resistance in myotubes induced by dexamethasone. Western blotting results indicated that esculin, fraxetin and osthole could boost Akt activation, stimulate GLUT4 translocation, thus alleviate insulin resistance. Esculin and osthole also could activate AMPK, thereby phosphorylate TBC1D1 at Ser237, and consequently ameliorate diabetogenic action of dexamethasone. Our study indicates coumarins as potential anti-diabetic candidates or leading compounds for drug development.

Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

KEYWORDS

Coumarin; Dexamethasone; Esculin; Fraxetin; Insulin resistance; Osthole

Title

Coumarins ameliorate diabetogenic action of dexamethasone via Akt activation and AMPK signaling in skeletal muscle.

Author

Mo Z1, Li L2, Yu H2, Wu Y2, Li H3.

Publish date

2019 Mar